WO2005026733A1 - Method and device for detecting feline immunodeficiency virus - Google Patents
Method and device for detecting feline immunodeficiency virus Download PDFInfo
- Publication number
- WO2005026733A1 WO2005026733A1 PCT/US2004/029570 US2004029570W WO2005026733A1 WO 2005026733 A1 WO2005026733 A1 WO 2005026733A1 US 2004029570 W US2004029570 W US 2004029570W WO 2005026733 A1 WO2005026733 A1 WO 2005026733A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fiv
- seq
- polypeptide
- vaccinated
- infected
- Prior art date
Links
- 241000713800 Feline immunodeficiency virus Species 0.000 title claims abstract description 235
- 238000000034 method Methods 0.000 title claims abstract description 58
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 119
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 116
- 229920001184 polypeptide Polymers 0.000 claims abstract description 106
- 241001465754 Metazoa Species 0.000 claims abstract description 75
- 239000000523 sample Substances 0.000 claims abstract description 41
- 238000002255 vaccination Methods 0.000 claims abstract description 35
- 239000012472 biological sample Substances 0.000 claims abstract description 22
- 230000028993 immune response Effects 0.000 claims abstract description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 68
- 108090000623 proteins and genes Proteins 0.000 claims description 45
- 102000004169 proteins and genes Human genes 0.000 claims description 42
- 229960005486 vaccine Drugs 0.000 claims description 39
- 208000015181 infectious disease Diseases 0.000 claims description 38
- 238000012360 testing method Methods 0.000 claims description 38
- 241000282326 Felis catus Species 0.000 claims description 37
- 238000001514 detection method Methods 0.000 claims description 36
- 150000001413 amino acids Chemical class 0.000 claims description 25
- 230000004044 response Effects 0.000 claims description 18
- 108010078428 env Gene Products Proteins 0.000 claims description 16
- 102100034353 Integrase Human genes 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 230000000890 antigenic effect Effects 0.000 claims description 7
- 230000005875 antibody response Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000009739 binding Methods 0.000 abstract description 20
- 230000027455 binding Effects 0.000 abstract description 19
- 230000009385 viral infection Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 36
- 235000001014 amino acid Nutrition 0.000 description 25
- 230000009870 specific binding Effects 0.000 description 16
- 238000003556 assay Methods 0.000 description 13
- 241000700605 Viruses Species 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 239000012491 analyte Substances 0.000 description 10
- 101710177291 Gag polyprotein Proteins 0.000 description 9
- 101710125418 Major capsid protein Proteins 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 101710205625 Capsid protein p24 Proteins 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 101710177166 Phosphoprotein Proteins 0.000 description 7
- 101710149279 Small delta antigen Proteins 0.000 description 7
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 239000000178 monomer Substances 0.000 description 7
- 239000007790 solid phase Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 102000003992 Peroxidases Human genes 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 108040007629 peroxidase activity proteins Proteins 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 241000282324 Felis Species 0.000 description 4
- 102100034349 Integrase Human genes 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 108700004029 pol Genes Proteins 0.000 description 3
- 101150088264 pol gene Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 239000006226 wash reagent Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 108700004025 env Genes Proteins 0.000 description 2
- 101150030339 env gene Proteins 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108700004026 gag Genes Proteins 0.000 description 2
- 101150098622 gag gene Proteins 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000012898 sample dilution Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- 101100452236 Caenorhabditis elegans inf-1 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282323 Felidae Species 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 241001455213 Leopardus pardalis Species 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 241000282372 Panthera onca Species 0.000 description 1
- 241000282373 Panthera pardus Species 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 241000282374 Puma concolor Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000010094 Visna Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011982 device technology Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000005571 horizontal transmission Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000009448 modified atmosphere packaging Methods 0.000 description 1
- 235000019837 monoammonium phosphate Nutrition 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000019722 synbiotics Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
- G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT04783703T ATE435425T1 (en) | 2003-09-11 | 2004-09-10 | METHOD FOR DETECTING FELINE IMMUNO DEFICIENCY VIRUS |
AU2004273076A AU2004273076B2 (en) | 2003-09-11 | 2004-09-10 | Method and device for detecting feline immunodeficiency virus |
EP04783703A EP1673633B9 (en) | 2003-09-11 | 2004-09-10 | Method for detecting feline immunodeficiency virus |
DE602004021829T DE602004021829D1 (en) | 2003-09-11 | 2004-09-10 | METHOD FOR DETECTING THE FELINE IMMUNE WEAK VIRUS |
CA002537429A CA2537429A1 (en) | 2003-09-11 | 2004-09-10 | Method and device for detecting feline immunodeficiency virus |
JP2006526311A JP2007505320A (en) | 2003-09-11 | 2004-09-10 | Method and apparatus for detection of feline immunodeficiency virus |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50198203P | 2003-09-11 | 2003-09-11 | |
US60/501,982 | 2003-09-11 | ||
US58410604P | 2004-06-30 | 2004-06-30 | |
US60/584,106 | 2004-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005026733A1 true WO2005026733A1 (en) | 2005-03-24 |
Family
ID=34316504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/029570 WO2005026733A1 (en) | 2003-09-11 | 2004-09-10 | Method and device for detecting feline immunodeficiency virus |
Country Status (9)
Country | Link |
---|---|
US (3) | US7201903B2 (en) |
EP (2) | EP1673633B9 (en) |
JP (1) | JP2007505320A (en) |
AT (1) | ATE435425T1 (en) |
AU (1) | AU2004273076B2 (en) |
CA (1) | CA2537429A1 (en) |
DE (1) | DE602004021829D1 (en) |
ES (1) | ES2327340T3 (en) |
WO (1) | WO2005026733A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005062053A2 (en) * | 2003-12-18 | 2005-07-07 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
WO2005080939A3 (en) * | 2004-02-19 | 2005-10-06 | Idexx Lab Inc | Method and device for detecting feline immunodeficiency virus |
WO2006011920A1 (en) * | 2004-06-30 | 2006-02-02 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus (fiv) comprising the use of peptides derived from the v3 region of the fiv env protein |
WO2006011919A1 (en) * | 2004-06-30 | 2006-02-02 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
WO2006098849A2 (en) * | 2005-03-09 | 2006-09-21 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1800126B1 (en) * | 2004-09-08 | 2014-12-17 | The United States of America as represented by the Secretary of Health and Human Services, NIH | Compositions and methods for the detection of hiv-1/hiv-2 infection |
WO2011123781A1 (en) | 2010-04-02 | 2011-10-06 | Idexx Laboratories, Inc. | Detection of feline immunodeficiency virus |
CN109734783A (en) * | 2018-12-26 | 2019-05-10 | 杭州爱谨生物科技有限公司 | A kind of cat AIDS poison recombinant protein and its preparation method and application |
JP6976621B1 (en) * | 2021-02-04 | 2021-12-08 | 株式会社Icst | Inspection equipment, inspection kits and inspection methods |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458528B1 (en) * | 1998-05-15 | 2002-10-01 | Idexx Laboratories, Inc. | Diagnosis of feline immunodeficiency virus infection using ENV/GAG polypeptide markers |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4629783A (en) | 1985-04-29 | 1986-12-16 | Genetic Systems Corporation | Synthetic antigen for the detection of AIDS-related disease |
US4879212A (en) | 1986-04-02 | 1989-11-07 | United Biomedical Inc. | Peptide composition and method for the detection of antibodies to HTLV-III |
US5118602A (en) | 1987-08-26 | 1992-06-02 | The Regents Of The University Of California | Feline T-lymphotropic lentivirus assay |
CA1341439C (en) | 1987-08-26 | 2003-09-23 | Niels C. Pedersen | Feline t-lymphotropic lentivirus |
US4900548A (en) | 1987-11-13 | 1990-02-13 | Harvard University | Use of diethylcarbamazine to enhance antigen-antibody and antigen-host immune cell interactions |
JPH0211524A (en) | 1988-06-29 | 1990-01-16 | Gen Corp:Kk | Preparation of aujesky's disease vaccine and discrimination of swine inoculated with the same vaccine from swine infected by natural infection |
CA1335880C (en) | 1988-07-14 | 1995-06-13 | Thomas P. O'connor | Detection of an antibody and antigen in an immunoassay |
US5177014A (en) | 1988-12-05 | 1993-01-05 | Idexx Laboratories, Inc. | Monoclonal antibodies to feline-T-lymphotropic lentivirus |
US5219725A (en) | 1988-12-05 | 1993-06-15 | Idexx Laboratories Incorporated | Monoclonal antibodies to feline-t-lymphotropic lentivirus |
EP0860504A1 (en) | 1989-05-08 | 1998-08-26 | Idexx Laboratories, Inc. | Polypeptides of feline T-cell lymphotropic lentivirus |
FR2669338A1 (en) | 1990-11-21 | 1992-05-22 | Centre Nat Rech Scient | PEPTIDE FRAGMENTS FROM THE EXTERNAL PROTEIN OF FIV, ANTIFORING ANTIBODIES, APPLICATION THEREOF TO THE DIAGNOSIS AND / OR TREATMENT OF FELINE IMMUNODEFICIENCY |
US6228608B1 (en) | 1991-02-28 | 2001-05-08 | Aquila Biopharmaceuticals, Inc. | Recombinant FIV glycoprotein 160 and P24 gag protein |
DE69223250T3 (en) | 1991-06-14 | 2008-02-28 | Idexx Laboratories, Inc. | DETECTION OF IMMUNE WEAKNESS VIRUS FROM FELIS |
WO1993001304A1 (en) | 1991-07-10 | 1993-01-21 | Synbiotics Corporation | Synthetic peptides related to fiv-env proteins |
US5726010A (en) | 1991-07-31 | 1998-03-10 | Idexx Laboratories, Inc. | Reversible flow chromatographic binding assay |
US5736378A (en) | 1991-09-12 | 1998-04-07 | The Scripps Research Institute | Molecular cloning and characterization of the feline immunodeficiency virus isolate PPR |
EP0577458B1 (en) | 1992-06-16 | 2004-09-29 | Centre National De La Recherche Scientifique | Nucleotide and Peptide sequences of the FIV isolate WO and their uses in diagnostic and prevention of the feline immunodeficiency virus infection |
GB9215232D0 (en) | 1992-07-17 | 1992-09-02 | Pitman Moore Inc | Vaccines |
GB9219936D0 (en) | 1992-09-21 | 1992-11-04 | Pitman Moore Inc | Vaccines |
US5462852A (en) | 1992-10-28 | 1995-10-31 | The Government Of The United States Of America, As Represented By The Secretary, Dhhs | HIV Nucleocapsid protein capture assay and method of use |
DE4242475A1 (en) | 1992-12-16 | 1994-06-23 | Suspa Compart Ag | Guide bushing, in particular for length-adjustable chair column and chair column with such a guide bushing |
JPH07159408A (en) | 1993-12-09 | 1995-06-23 | Biseibutsu Kagaku Kenkyusho:Kk | Antigen for identifying aujeszky's desease virus-infected antibody |
US5576177A (en) | 1994-03-09 | 1996-11-19 | St. Jude Children's Research Hospital | Bioassay for reverse transcriptase inhibitors |
EP0758396B1 (en) | 1994-04-29 | 2006-07-26 | Pharmacia & Upjohn Company LLC | Feline immunodeficiency virus vaccine |
FR2721031B1 (en) * | 1994-06-09 | 1996-07-26 | Centre Nat Rech Scient | Feline immunodeficiency virus (VIF) specific peptide fragment and its use as a diagnostic reagent. |
AU688953B2 (en) | 1994-07-25 | 1998-03-19 | Boehringer Mannheim Gmbh | Determination of a specific immunoglobulin using multiple antigens |
US5675056A (en) | 1995-03-09 | 1997-10-07 | Vance; Murray A. | Incandescent waste disposal system and method |
FR2732346B1 (en) | 1995-03-27 | 1997-05-30 | Centre Nat Rech Scient | MUTE PROTEINS, ENCODED BY LENTIVIRUS MUTE GENES, PEPTIDE FRAGMENTS INCLUDED IN SAID PROTEINS, EXPRESSION VECTORS EXPRESSING MUTE PROTEINS AND THEIR APPLICATIONS |
US6300118B1 (en) | 1995-06-07 | 2001-10-09 | American Home Products Corporation | Plasmids comprising a genetically altered feline immunodeficiency virus genome |
US5849303A (en) | 1995-06-07 | 1998-12-15 | American Home Products Corporation | Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection |
US5820869A (en) | 1995-06-07 | 1998-10-13 | American Home Products Corporation | Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection |
US6254872B1 (en) | 1995-08-25 | 2001-07-03 | University Of Florida | Multi-subtype FIV vaccines |
IL163873A0 (en) | 1995-08-25 | 2005-12-18 | Univ Florida | Il-2 independent feline derived T cell |
US6077662A (en) | 1996-11-27 | 2000-06-20 | Emory University | Virus-like particles, methods and immunogenic compositions |
US6331616B1 (en) | 1997-03-05 | 2001-12-18 | North Carolina State University | Nucleic acids obtained from the envelope coding region of feline immunodeficiency virus molecular clone designated JSY3 |
EP0887412B1 (en) | 1997-05-26 | 2003-10-15 | Akzo Nobel N.V. | Recombinant birnavirus vaccine |
FR2769916B1 (en) | 1997-10-17 | 2000-12-01 | Centre Nat Rech Scient | PEPTIDES FROM THE ENV GENE OF THE FELINE IMMUNODEFICIENCY VIRUS AND THEIR IMMUNOPROTECTIVE AND VACCINE APPLICATIONS |
FR2771011B1 (en) | 1997-11-17 | 2000-01-28 | Hippocampe | OBTAINING VACCINES TO PREVENT PATHOGENIC EFFECTS ASSOCIATED WITH RETROVIRAL INFECTION |
DE1035780T1 (en) | 1997-12-05 | 2001-02-08 | Univ New Mexico Albuquerque | METHOD FOR CLEANING HEAT-SHOCK PEPTIDE COMPLEXES |
US6284253B1 (en) | 1998-01-29 | 2001-09-04 | Cornell Research Foundation, Inc. | Feline immunodeficiency virus (FIV) nucleotide sequence |
US6764676B1 (en) | 1998-08-24 | 2004-07-20 | Pfizer Inc. | Compositions and methods for protecting animals from lentivirus-associated disease such as feline immunodeficiency virus |
EP1074625A3 (en) * | 1999-06-14 | 2002-01-02 | Pfizer Products Inc. | DNA vaccine against feline immunodeficiency virus |
ATE294857T1 (en) | 1999-07-08 | 2005-05-15 | Mologen Forschungs Entwicklung | VACCINE AGAINST INFECTIONS WITH LENTIVIRUS, SUCH AS THE FELINE IMMUNE DEFICIENCY VIRUS IN CAT |
US6420591B1 (en) | 1999-10-04 | 2002-07-16 | University Of Medicine And Dentistry Of New Jersey | Carbamates and compositions thereof, and methods for their use for treating cancer, inflammation, or a viral infection |
US20040115621A1 (en) * | 2000-02-18 | 2004-06-17 | Allen Rodrigo | Ancestral viruses and vaccines |
FR2828687B1 (en) | 2001-08-17 | 2003-12-12 | Hippocampe | NOVEL PEPTIDES AND THEIR USE AS MEDICAMENTS AGAINST IVF INFECTION IN CATS |
CN100387301C (en) | 2003-05-12 | 2008-05-14 | 佛罗里达大学研究基金公司 | Materials and methods for immunizing against fiv infection. |
-
2004
- 2004-09-10 US US10/938,056 patent/US7201903B2/en not_active Expired - Fee Related
- 2004-09-10 EP EP04783703A patent/EP1673633B9/en not_active Not-in-force
- 2004-09-10 AT AT04783703T patent/ATE435425T1/en not_active IP Right Cessation
- 2004-09-10 JP JP2006526311A patent/JP2007505320A/en active Pending
- 2004-09-10 AU AU2004273076A patent/AU2004273076B2/en not_active Ceased
- 2004-09-10 ES ES04783703T patent/ES2327340T3/en active Active
- 2004-09-10 US US10/938,097 patent/US7776546B2/en active Active
- 2004-09-10 EP EP09003215A patent/EP2107374A1/en not_active Withdrawn
- 2004-09-10 CA CA002537429A patent/CA2537429A1/en not_active Abandoned
- 2004-09-10 DE DE602004021829T patent/DE602004021829D1/en active Active
- 2004-09-10 WO PCT/US2004/029570 patent/WO2005026733A1/en active Application Filing
-
2010
- 2010-04-15 US US12/761,239 patent/US20110189651A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458528B1 (en) * | 1998-05-15 | 2002-10-01 | Idexx Laboratories, Inc. | Diagnosis of feline immunodeficiency virus infection using ENV/GAG polypeptide markers |
Non-Patent Citations (7)
Title |
---|
CALANDRELLA M ET AL: "Densitometric analysis of Western blot assays for feline immunodeficiency virus antibodies", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 79, no. 3-4, 30 May 2001 (2001-05-30), pages 261 - 271, XP002312661, ISSN: 0165-2427 * |
HARTMANN K ET AL: "Comparison of six in-house tests for the rapid diagnosis of feline immunodeficiency and feline leukaemia virus infections.", THE VETERINARY RECORD. 15 SEP 2001, vol. 149, no. 11, 15 September 2001 (2001-09-15), pages 317 - 320, XP008040870, ISSN: 0042-4900 * |
HOHDATSU TSUTOMU ET AL: "Effect of dual-subtype vaccine against feline immunodeficiency virus infection", VETERINARY MICROBIOLOGY, vol. 58, no. 2-4, November 1997 (1997-11-01), pages 155 - 165, XP002312712, ISSN: 0378-1135 * |
MOON DEBRA: "Another solution to identify FIV-vaccinated cats.", JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION. 1 MAY 2003, vol. 222, no. 9, 1 May 2003 (2003-05-01), pages 1207; author reply 1207, XP008040879, ISSN: 0003-1488 * |
MURRAY DOROTHY M: "Identifying FIV vaccinates.", JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, vol. 222, no. 6, 15 March 2003 (2003-03-15), pages 710, XP008040878, ISSN: 0003-1488 * |
UHL E W ET AL: "FIV vaccine development and its importance to veterinary and human medicine: A review FIV vaccine 2002 update and review.", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 90, no. 3-4, December 2002 (2002-12-01), pages 113 - 132, XP002312660, ISSN: 0165-2427 * |
YAMAMOTO J K ET AL: "EXPERIMENTAL VACCINE PROTECTION AGAINST HOMOLOGOUS AND HETEROLOGOUSSTRAINS OF FELINE IMMUNODEFICIENCY VIRUS", JOURNAL OF VIROLOGY, NEW YORK, US, US, vol. 67, no. 1, 1993, pages 601 - 605, XP000609625, ISSN: 0022-538X * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005267607B2 (en) * | 2003-09-11 | 2009-06-11 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
AU2005267607B8 (en) * | 2003-09-11 | 2009-07-16 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
WO2005062053A2 (en) * | 2003-12-18 | 2005-07-07 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
WO2005062053A3 (en) * | 2003-12-18 | 2005-09-29 | Idexx Lab Inc | Method and device for detecting feline immunodeficiency virus |
WO2005080939A3 (en) * | 2004-02-19 | 2005-10-06 | Idexx Lab Inc | Method and device for detecting feline immunodeficiency virus |
WO2006011920A1 (en) * | 2004-06-30 | 2006-02-02 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus (fiv) comprising the use of peptides derived from the v3 region of the fiv env protein |
WO2006011919A1 (en) * | 2004-06-30 | 2006-02-02 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
WO2006098849A2 (en) * | 2005-03-09 | 2006-09-21 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
WO2006098849A3 (en) * | 2005-03-09 | 2007-04-19 | Idexx Lab Inc | Method and device for detecting feline immunodeficiency virus |
AU2006223631B2 (en) * | 2005-03-09 | 2009-12-17 | Idexx Laboratories Inc. | Method and device for detecting feline immunodeficiency virus |
Also Published As
Publication number | Publication date |
---|---|
AU2004273076B2 (en) | 2008-02-14 |
US20110189651A1 (en) | 2011-08-04 |
US7201903B2 (en) | 2007-04-10 |
DE602004021829D1 (en) | 2009-08-13 |
EP2107374A1 (en) | 2009-10-07 |
US7776546B2 (en) | 2010-08-17 |
ATE435425T1 (en) | 2009-07-15 |
AU2004273076A1 (en) | 2005-03-24 |
CA2537429A1 (en) | 2005-03-24 |
EP1673633B1 (en) | 2009-07-01 |
EP1673633B9 (en) | 2011-03-02 |
US20050058993A1 (en) | 2005-03-17 |
US20050058992A1 (en) | 2005-03-17 |
ES2327340T3 (en) | 2009-10-28 |
EP1673633A1 (en) | 2006-06-28 |
JP2007505320A (en) | 2007-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110189651A1 (en) | Method and Device for Detecting Feline Immunodeficiency Virus | |
AU2005267605B2 (en) | Method and device for detecting feline immunodeficiency virus | |
US7285272B2 (en) | Method and device for detecting feline immunodeficiency virus | |
AU2005267607B8 (en) | Method and device for detecting feline immunodeficiency virus | |
US7348136B2 (en) | Method and device for detecting feline immunodeficiency virus | |
US7335360B2 (en) | Method and device for detecting feline immunodeficiency virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004273076 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006526311 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2537429 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2004273076 Country of ref document: AU Date of ref document: 20040910 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004273076 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004783703 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004783703 Country of ref document: EP |